34.84 USD
+0.53 (+1.54%)
HRMY gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! This makes HRMY very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
In the past year HRMY had a positive cash flow from operations.
Of the past 5 years HRMY 4 years were profitable.
HRMY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HRMY has a Return On Assets of 15.37%. This is amongst the best in the industry. HRMY outperforms 95.83% of its industry peers.
HRMY has a Return On Equity of 22.23%. This is amongst the best in the industry. HRMY outperforms 92.71% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.20%, HRMY belongs to the top of the industry, outperforming 94.27% of the companies in the same industry.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is significantly above the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROIC | 17.2% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
HRMY's Profit Margin of 22.48% is amongst the best of the industry. HRMY outperforms 92.19% of its industry peers.
In the last couple of years the Profit Margin of HRMY has grown nicely.
HRMY's Operating Margin of 27.32% is amongst the best of the industry. HRMY outperforms 93.23% of its industry peers.
In the last couple of years the Operating Margin of HRMY has declined.
HRMY has a better Gross Margin (77.70%) than 82.29% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HRMY is creating value.
The number of shares outstanding for HRMY has been increased compared to 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
The debt/assets ratio for HRMY has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.25 indicates that HRMY is not in any danger for bankruptcy at the moment.
HRMY has a Altman-Z score of 5.25. This is in the better half of the industry: HRMY outperforms 76.56% of its industry peers.
HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.57, HRMY belongs to the top of the industry, outperforming 96.35% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that HRMY is not too dependend on debt financing.
HRMY's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. HRMY outperforms 47.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Altman-Z | 5.25 |
ROIC/WACC1.9
WACC9.04%
2.3 Liquidity
A Current Ratio of 3.75 indicates that HRMY has no problem at all paying its short term obligations.
The Current ratio of HRMY (3.75) is comparable to the rest of the industry.
HRMY has a Quick Ratio of 3.72. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a Quick ratio (3.72) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.71%, which is quite impressive.
Measured over the past years, HRMY shows a very strong growth in Earnings Per Share. The EPS has been growing by 44.61% on average per year.
HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.13%.
The Revenue has been growing by 160.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
3.2 Future
HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.90% yearly.
HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.35% yearly.
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.96, which indicates a very decent valuation of HRMY.
Based on the Price/Earnings ratio, HRMY is valued cheaper than 90.10% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 25.47, HRMY is valued rather cheaply.
A Price/Forward Earnings ratio of 8.44 indicates a reasonable valuation of HRMY.
Based on the Price/Forward Earnings ratio, HRMY is valued cheaply inside the industry as 89.58% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.42, HRMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.96 | ||
| Fwd PE | 8.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaper than 96.35% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 93.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.75 | ||
| EV/EBITDA | 5.79 |
4.3 Compensation for Growth
HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 27.97% in the coming years.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y28.23%
EPS Next 3Y27.97%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HRMY (11/24/2025, 12:36:00 PM)
34.84
+0.53 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.62%
Inst Owner Change-7.66%
Ins Owners0.52%
Ins Owner Change-61.56%
Market Cap2.00B
Revenue(TTM)825.94M
Net Income(TTM)185.68M
Analysts78.82
Price Target46.46 (33.35%)
Short Float %8.06%
Short Ratio4.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)2.24%
PT rev (3m)-9.89%
EPS NQ rev (1m)-7.51%
EPS NQ rev (3m)-0.62%
EPS NY rev (1m)1.1%
EPS NY rev (3m)1.89%
Revenue NQ rev (1m)0.7%
Revenue NQ rev (3m)0.95%
Revenue NY rev (1m)0.49%
Revenue NY rev (3m)0.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.96 | ||
| Fwd PE | 8.44 | ||
| P/S | 2.43 | ||
| P/FCF | 6.75 | ||
| P/OCF | 6.73 | ||
| P/B | 2.4 | ||
| P/tB | 2.71 | ||
| EV/EBITDA | 5.79 |
EPS(TTM)3.18
EY9.13%
EPS(NY)4.13
Fwd EY11.85%
FCF(TTM)5.16
FCFY14.81%
OCF(TTM)5.17
OCFY14.85%
SpS14.36
BVpS14.52
TBVpS12.86
PEG (NY)0.36
PEG (5Y)N/A
Graham Number32.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.37% | ||
| ROE | 22.23% | ||
| ROCE | 22.91% | ||
| ROIC | 17.2% | ||
| ROICexc | 54.26% | ||
| ROICexgc | 78.12% | ||
| OM | 27.32% | ||
| PM (TTM) | 22.48% | ||
| GM | 77.7% | ||
| FCFM | 35.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 0.57 | ||
| Debt/EBITDA | 0.6 | ||
| Cap/Depr | 3% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | 14.73 | ||
| Cash Conversion | 119.28% | ||
| Profit Quality | 159.9% | ||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z | 5.25 |
F-Score6
WACC9.04%
ROIC/WACC1.9
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.71%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%10.13%
EPS Next Y30.15%
EPS Next 2Y28.23%
EPS Next 3Y27.97%
EPS Next 5Y34.9%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%28.71%
Revenue Next Year18.42%
Revenue Next 2Y17.17%
Revenue Next 3Y15.73%
Revenue Next 5Y14.35%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year36.94%
EBIT Next 3Y27.36%
EBIT Next 5Y22.83%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A
HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ
Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a fundamental rating of 8 / 10 to HRMY.
Can you provide the valuation status for HARMONY BIOSCIENCES HOLDINGS?
ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.
Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?
HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.
What is the valuation of HARMONY BIOSCIENCES HOLDINGS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.96 and the Price/Book (PB) ratio is 2.4.